顺铂
细胞毒性
纳米医学
缺氧(环境)
提拉帕扎明
细胞内
光动力疗法
癌症研究
癌细胞
化学
抗药性
肿瘤缺氧
药理学
癌症
医学
生物
体外
放射治疗
纳米技术
材料科学
化疗
生物化学
内科学
纳米颗粒
氧气
有机化学
微生物学
作者
Yurong Liu,Longqing Si,Yunheng Liu,Li Song,Xiaokang Zhang,Shaojing Jiang,Wenjing Liu,Xiaolin Li,Lianguo Zhang,Hongxia Zheng,Zhonghao Liu,Jinghui Hu,Jing Chen
标识
DOI:10.1016/j.mtbio.2025.101709
摘要
Cancer poses a significant threat to human life and health. Cancers treated with cisplatin invariably develop drug resistance. This challenge can be overcome by identifying and exploiting the vulnerabilities acquired by drug-resistant cancer cells, paving the way for finding effective novel treatment options for cisplatin-resistant cancers. Our previous study revealed that cisplatin resistance in cancer cells comes at the cost of increased intracellular hypoxia. In this study, we used 2-nitroimidazole modified hyaluronic acid (HA-NI) as the carrier. The cisplatin-resistant tumor cell specific intracellular hypoxia programmed activation nanomedicine (T/C@HN NPs) was constructed by the hypoxic toxic drug tirapazamine (TPZ) and encapsulating chlorin e6 (Ce6) into HA-NI using polymer assembly technology. The amphiphilic carrier could release free Ce6 molecules under the stimulation of intracellular hypoxic environment, and exhibit specific "activated state" photodynamic properties in cisplatin-resistant tumor cells. Upon irradiation, Ce6-mediated photodynamic therapy further intensifies hypoxia, amplifying its cytotoxicity. This project systematically evaluated the effects of T/C@HN NPs on the identification and recognition of cisplatin-resistant tumors using drug-resistant patient-derived xenograft (PDX) models. This study provides a promising avenue for the development of novel treatment of cisplatin-resistant tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI